Back to discover
Disease

Schistosomiasis

Late-stage therapeutic developmentEmerging research
MeSHSchistosomiasis
2
Publications
8
Clinical trials
1
Related conditions
2025
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 industry development reported.
Industry & Market1View
Activity timeline1

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
8
All trials
0
Active
6
Late-stage
6
Completed
Late-stage studies

An Open Label, Phase III Efficacy and Safety Study of L-PZQ ODT in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®)

Phase 3 · Completed · Merck KGaA, Darmstadt, Germany

Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children

Phase 3 · Completed · Institut National de la Santé Et de la Recherche Médicale, France

Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

Phase 2/3 · Completed · Regionshospital Nordjylland

Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study

Phase 3 · Completed · Pharco Pharmaceuticals

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire

Phase 3 · Completed · Leiden University Medical Center

Effect of Concomitant Mansonella Perstans Microfilaremia on Immune Responses Following Single Dose Praziquantel in Subjects With Schistosomiasis: A Pilot Study

Phase 4 · Withdrawn · National Institute of Allergy and Infectious Diseases (NIAID)
Recently completed

An Open Label, Phase III Efficacy and Safety Study of L-PZQ ODT in Schistosoma Infected Children 3 Months to 6 Years of Age, Including a 2:1 Randomized, Controlled Cohort of Schistosoma Mansoni Infected Children 4 to 6 Years of Age Treated With L PZQ ODT or Commercial PZQ (Biltricide®)

Phase 3 · Completed · Merck KGaA, Darmstadt, Germany

Treatment of Female Genital Schistosomiasis (FGS) With Praziquantel: A Proof-of-Concept Study

Phase 2/3 · Completed · Regionshospital Nordjylland

Repeated Doses of Praziquantel in Schistosomiasis Treatment (RePST): An Open Label, Randomized Controlled Trial of Single vs. Multiple Treatments of Praziquantel in Intestinal African Schistosomiasis in Côte d'Ivoire

Phase 3 · Completed · Leiden University Medical Center

Intestinal Schistosomiasis in Children Aged 1-5 Years,Morbidity Assessment and the Effect of Praziquantel on Morbidity; Along Lake Victoria Shorelines.

Phase 2 · Completed · Makerere University

Safety and Efficacy of Mirazid for Schistosomiasis Treatment as Compared to Praziquantel: An Open-label Randomized Non-placebo-Controlled Study

Phase 3 · Completed · Pharco Pharmaceuticals

Efficacy and Safety Evaluation of the Therapeutic Vaccine Candidate Sh28GST in Association With Praziquantel (PZQ) for Prevention of Clinical and Parasitological Recurrences of S. Haematobium Infection in Children

Phase 3 · Completed · Institut National de la Santé Et de la Recherche Médicale, France

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20242025
Major themes6
  • Neglected Diseases2
  • Disability-Adjusted Life Years1
  • Disease Eradication1
  • Global Burden of Disease1
  • Tropical Medicine1
  • World Health Organization1
Leading journals2
  • BMJ (Clinical research ed.)1
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases1
Leading researchers8
  • Achu D1
  • Barry A1
  • Campos A1
  • Djirmay AG1
  • Fall IS1
  • Farham B1
  • Impouma B1
  • Juma E1
Affiliations (unnormalised)4
  • Congo; University of South Florida College of Public Health1
  • National Institute of Parasitic Diseases at Chinese Center for Disease Control and Prevention1
  • NHC Key Laboratory of Tropical Disease Control1
  • One Health Center1

Related conditions

1 match

Diseases frequently studied alongside this one. Number shows shared papers.

Neglected Diseases2

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Infection with flukes (trematodes) of the genus SCHISTOSOMA. Three species produce the most frequent clinical diseases: SCHISTOSOMA HAEMATOBIUM (endemic in Africa and the Middle East), SCHISTOSOMA MANSONI (in Egypt, northern and southern Africa, some West Indies islands, northern 2/3 of South America), and SCHISTOSOMA JAPONICUM (in Japan, China, the Philippines, Celebes, Thailand, Laos). S. mansoni is often seen in Puerto Ricans living in the United States.

Identifiers
MeSHSchistosomiasis
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.